Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/6/2025

Management of Nasal Congestion in Patients on Montelukast

Primary Recommendation: Intranasal Antihistamine

  • The American Academy of Allergy, Asthma, and Immunology recommends adding an intranasal antihistamine, such as azelastine, to montelukast for patients with nasal congestion, as it provides clinically significant relief with rapid onset of action 1, 2
  • Azelastine is effective for both allergic and vasomotor rhinitis, making it suitable for mixed rhinitis, with a strength of evidence supporting its use 1, 2
  • Common side effects of azelastine include bitter taste and mild somnolence, but these are generally well-tolerated 1, 2

Alternative Option: Oral Decongestant

  • Pseudoephedrine, an oral decongestant, reduces nasal congestion and can be used short-term if intranasal options are refused, with a moderate strength of evidence supporting its use 1, 2
  • Side effects of pseudoephedrine include insomnia, irritability, palpitations, and hypertension, requiring screening for cardiovascular contraindications before prescribing 1, 2

What NOT to Do

  • The American Academy of Allergy, Asthma, and Immunology advises against adding another oral antihistamine to montelukast, as oral antihistamines are less effective for nasal congestion, with a low strength of evidence supporting this combination 1, 2
  • Topical nasal decongestants, such as oxymetazoline and phenylephrine, should be avoided beyond 3-5 days to prevent rhinitis medicamentosa, with a high strength of evidence supporting this recommendation 3

Important Clinical Context

  • Montelukast has similar efficacy to oral antihistamines but is less effective for nasal congestion specifically, with a moderate strength of evidence supporting its use 1, 2
  • Intranasal antihistamines work through a different mechanism than montelukast and provide additive benefit, with a high strength of evidence supporting their use 1, 2

If Symptoms Remain Inadequately Controlled

  • Adding an oral second-generation antihistamine, such as cetirizine, loratadine, or fexofenadine, can provide additional symptom control of sneezing, itching, and rhinorrhea, but has minimal impact on congestion, with a low strength of evidence supporting this approach 1, 2
  • Referral for allergen immunotherapy is recommended if symptoms persist despite optimal pharmacotherapy, as it provides long-term disease modification, with a high strength of evidence supporting its use 4
  • Saline nasal irrigation provides modest additional benefit and can be used adjunctively, with a moderate strength of evidence supporting its use 5

REFERENCES

4

Management of Allergic Rhinitis Inadequately Controlled by Montelukast [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025